BLSI Boston Life Sciences (MM)

HOPKINTON, Mass., July 27 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that it has appointed William L.S. Guinness to its Board of Directors. "I am very pleased that Billy Guinness has agreed to join our board," stated BLSI chairman Peter Savas. "He is committed to the medical needs targeted by our current programs in Parkinson's disease, tremor, stroke and optic nerve injury. Equally important is his interest, as well as his ability to contribute to our plans to strengthen BLSI's product pipeline through strategic transactions with other promising companies. Billy's corporate development and financial skills along with his access to extensive international resources and relationships adds critical capabilities to our board." "I am extremely pleased to serve on the Board of BLSI, a company with an unwavering commitment to developing sorely needed diagnostics and therapeutics for the treatment of central nervous system disorders," stated Guinness. "My tenure on the BLSI board was a short one in 2003, but I have watched the Company with great interest and I am impressed with the Company's progress led by the current directors, officers and principal shareholders during the past two years. The Company's vision and growth strategy is compelling and I believe the Company has taken the appropriate steps to position itself to participate in a selective consolidation of the life science sector. I look forward to working closely with BLSI to guide the Company's future development, growth and value building efforts." Mr. Guinness has been Chairman of Sibir Energy plc since 1999 and had additional roles with Pentex Energy plc and Pentex Oil plc. Mr. Guinness has been involved with various private venture capital operations, which cover areas as diverse as metal manufacturing, general aviation, and fine art consultancy. Mr. Guinness is also a director of a number of private companies involved in a wide range of commercial activities. Mr. Guinness previously served on the Company's Board of Directors from June 30, 2003 to September 20, 2003. About BLSI: Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital of Boston. Statements in this press release regarding Boston Life Sciences' future performance including statements regarding the Company's future product pipeline and future strategic initiatives, including possible acquisitions of, or investments in, businesses, technologies and products that are complimentary to the Company's business, and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Boston Life Sciences' actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in Boston Life Sciences' Quarterly Report on Form 10-Q for the year ended March 31, 2006 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "should", "will", and "would" or similar words. Boston Life Sciences assumes no obligations to update the information in this press release. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT: Sharon Correia, +1-508-497-2360, ext. 224 of Boston Life Sciences, Inc., Web site: http://www.bostonlifesciences.com/

Copyright